Journal articles on the topic '914.25/4/003'
To see the other types of publications on this topic, follow the link: 914.25/4/003.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic '914.25/4/003.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Schleid, Thomas, and Falk Lissner. "Oxidsulfidchloride der Lanthanide vom Typ M4OS4Cl2 (M = La-Nd) / M4OS4Cl2-Type Oxysulfide Chlorides of the Lanthanides (M = La -Nd)." Zeitschrift für Naturforschung B 49, no. 3 (March 1, 1994): 340–46. http://dx.doi.org/10.1515/znb-1994-0309.
Full textAbstract:
Abstract Oxysulfide chlorides, M4OS4Cl2, of the lanthanides (M = La - Nd) are obtained upon the oxidation of the metals with sulfur in the presence of MOCl (or M2O3) and MCl3 in appropriate molar ratios. Additional NaCl or an excess of MCl3 serving as a flux provide even single crystalline material after reactions at 850 °C for seven days in sealed tantalum capsules. The crystal structure of M4OS4Cl2 (hexagonal, P63mc, no. 186, Z = 2; M = La: a = 933.19(3), c = 701.22(4) pm, c/a = 0.7514, R = RH = 0.020; M = Ce: a = 925.49(3), c = 694.13(3) pm, c/a = 0.7500; M = Pr: a = 919.72(4), c = 688.53(4) pm, c/a = 0.7486; M = Nd: a = 914.25(4), c = 683.12(4) pm, c/a = 0.7472, R = 0.022, Rw = 0.019) contains isolated O2--centered (M3+)4 tetrahedra which are surrounded by twelve S2- and six Cl-, capping vertices, edges, and faces of each tetrahedron and linking to other [OM4] units. Basically, the structure is identical to that of Ba4OCl6 if Ba2+ is substituted by M3+ and 2/3 of the CL- anions are replaced by S2- to secure charge neutrality in M4OS4Cl2. Different models for the Cl-/S2- replacement are presented on the basis of comparisons of the Madelung part of the lattice energy (MAPLE) with the MAPLE sum of the binaries (M2O3, M2S3, and MCl3).
2
Kott, A., C. Spear, D. Miller, A. Butler, and O. Markovic. "P.4.e.003 Proven methodology for selecting raters." European Neuropsychopharmacology 18 (August 2008): S498. http://dx.doi.org/10.1016/s0924-977x(08)70747-8.
Full text
3
Blakely, Martin L. "To the Editor (DOI: 10.1007/s00268-003-1024-4)." World Journal of Surgery 27, no. 12 (December 1, 2003): 1337. http://dx.doi.org/10.1007/s00268-003-1024-4.
Full text
4
Biswal, Shibadas, Jorge Fernando Mendez Galvan, Mercedes Macias Parra, Juan-Francisco Galan-Herrera, Monica Belisa Carrascal Rodriguez, Esteban Patricio Rodriguez Bueno, Manja Brose, et al. "Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City." Revista Panamericana de Salud Pública 45 (June 11, 2021): 1. http://dx.doi.org/10.26633/rpsp.2021.67.
Full textAbstract:
Objective. To describe the immunogenicity and safety of a tetravalent dengue vaccine (TAK-003) in healthy adolescents living in Mexico City, an area considered non-endemic for dengue (NCT03341637). Methods. Participants aged 12–17 years were randomized 3:1 to receive two doses (Month 0 and Month 3) of TAK-003 or placebo. Immunogenicity was assessed by microneutralization assay of dengue neutralizing antibodies at baseline, Months 4 and 9. Solicited and unsolicited adverse events (AEs) were recorded after each vaccination. Serious (SAEs) and medically-attended AEs (MAAEs) were recorded throughout the study. Results. 400 adolescents were enrolled, 391 (97.8%) completed the study. Thirty-six (9%) were baseline seropositive to ≥1 serotypes (reciprocal titer ≥10). Geometric mean titers (GMTs) in baseline seronegative TAK-003 recipients were 328, 1743, 120, and 143 at Month 4, and 135, 741, 46, and 38 at Month 9 against DENV-1, -2, -3, and -4, respectively. Placebo GMTs remained <10. Tetravalent seropositivity rates in vaccine recipients were 99.6% and 85.8% at Months 4 and 9, respectively. One MAAE in each group was considered treatment-related (TAK-003: injection-site erythema, and placebo: pharyngitis). Conclusion. TAK-003 was immunogenic against all four serotypes and was well tolerated in dengue-naïve adolescents living in Mexico City.
5
Shin, Soon Cheon, Beniamin Filimon, Yuefeng Yang, Zebin Hu, Vijayakrishna K. Gadi, and Weidong Xu. "Abstract 5078: Immune response markers following combination treatment with oncolytic adenovirus AMUN-003 and immune checkpoint inhibitors in a murine model of triple negative breast cancer." Cancer Research 83, no. 7_Supplement (April 4, 2023): 5078. http://dx.doi.org/10.1158/1538-7445.am2023-5078.
Full textAbstract:
Abstract Background: Accounting for about 10-15% of all breast cancer diagnoses, triple negative breast cancer (TNBC) has the highest mortality rate partly attributable to few effective treatment options. We evaluated a novel oncolytic adenovirus (rAd.sT.GM; named as AMUN-003 by AmunBio, Inc) encoding sTGFβRIIFc (a TGF-β protein decoy) and GM-CSF transgenes in combination with ICI treatments in the mouse TNBC 4T1 subcutaneous model. We previously reported that infection of target cancer cells with AMUN-003 and co-treatment with ICI led to potent inhibition of tumor progression and lung metastasis without off-target organ or systemic toxicity. Here, we provide details on the specific immune markers associated with responses. Methods: Immune competent BALB/C mice harboring 4T1 tumors were treated with combinations of anti-PD1 antibody, anti-CTLA antibody, AMUN-003 or sham injections. We measured inflammatory serum cytokines/chemokine levels by Meso Scale immunoassays and immune modulator gene expression in lung, spleen and tumor by qRT-PCR. Results: The “Triplet” combination of AMUN-003, anti-PD1 and anti-CTLA-4 antibodies was associated with decrease of poor prognosis biomarkers in serum: TGF-β1: Triplet p< 0.001, ICIs p<0.01, AMUN-003 p< 0.05; IL-27p28/IL-30: Triplet and ICIs p< 0.05; IL-1β: Triplet, AMUN-003, ICIs, and AMUN-003+anti-CTLA-4 p< 0.05; TNF-α: Triplet p< 0.01, ICIs p<0.05, and increase of immune stimulatory IFN-γ: Triplet p<0.01 (all compared to the buffer). In lung tissue, no significant changes in cytokine/chemokine expression were detected, however Granzyme B levels were significantly increased in Triplet: p< 0.05. In spleen, we detected increased cytokine expression (IL-2: Triplet, anti-CTLA-4, AMUN-003+anti-PD-1 p< 0.05; IL-4: Triplet p< 0.001, AMUN-003+anti-PD-1, AMUN-003+anti-CTLA-4: p< 0.01). In tumor, expression of TGF-β1 was significantly decreased by triplet and ICIs treatments (both p<0.05), but increases in IFN-γ, IL-4, CXCR4, and Perforin were observed in several treatment groups. Conclusions and Summary: Our data support the interpretation that the most potent intratumoral and systemic anti-tumor response took place with triplet therapy. Specifically, triplet therapy led to reduction of markers of systemic pathogenic inflammation but activation of anti-tumor cellular immunity (e.g., IFN-γ). In lung (site of 4T1 metastases), Granzyme B expression indicated activated NK cell and cytotoxic T cell infiltration was greatest in Triplet. Tumor expression data for IFN-γ, IL-4, CXCR4, and Perforin have limited interpretability because several animals had complete remissions at the primary tumor. Collectively, quantitative protein and expression immune response data presented here further support advancement of combination testing of AMUN-003 and ICIs in human clinical trials. Citation Format: Soon Cheon Shin, Beniamin Filimon, Yuefeng Yang, Zebin Hu, Vijayakrishna K Gadi, Weidong Xu. Immune response markers following combination treatment with oncolytic adenovirus AMUN-003 and immune checkpoint inhibitors in a murine model of triple negative breast cancer. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5078.
6
Heretik, A., V. Novotny, A. Heretik, J. Pecenak, and A. Ritomsky. "P.4.f.003 EPIA -anxiety as a trait in Slovakia." European Neuropsychopharmacology 16 (January 2006): S475—S476. http://dx.doi.org/10.1016/s0924-977x(06)70631-9.
Full text
7
Figlin, Robert A., Asim Amin, Arkadiusz Dudek, Theodore Logan, Raymond S. Lance, Jeffrey M. Holzbeierlein, Viraj A. Master, et al. "Phase II study combining personalized dendritic cell (DC)-based therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma (mRCC)." Journal of Clinical Oncology 30, no. 5_suppl (February 10, 2012): 348. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.348.
Full textAbstract:
348 Background: AGS-003 is a personalized immunotherapy that employs autologous DCs co-electroporated with the subject’s amplified tumor mRNA and synthetic CD40L RNA. Based on previous results with single agent AGS‐003 and acceptance of TKIs as the standard of care for mRCC, AGS-003 was evaluated in combination with sunitinib as initial treatment for advanced RCC. Progression free survival (PFS) results for the combination have been previously presented and show improvement compared to historical data in unfavorable risk patients treated with sunitinib alone. Methods: AGS-003-006 is an open label phase II study that included subjects with newly diagnosed, metastatic clear cell RCC. Tumor was harvested by nephrectomy or metastasectomy for mRNA. Autologous monocytes were collected by leukapheresis for the production of DCs. Subjects subsequently received sunitinib (4wks on, 2wks off) combined with AGS-003 (every 3wks X 5 doses, then every 12wks) until progression. AGS-003 doses consisted of 1 X 107 cells administered by intradermal injection to a single lymph node basin. Response was evaluated per RECIST and subjects followed for PFS and OS. Immune responses were assessed at baseline and after five AGS-003 doses using multiparametric flow cytometry. Results: 25 subjects were enrolled; 21 received treatment. The median PFS from registration for subjects receiving at least one dose of AGS-003 was 11.9 months. For subjects with 1–2 MSKCC risk factors (intermediate risk), PFS = 14.9 months and for subjects with 3–4 MSKCC risk factors (poor risk), PFS = 6.0 months. Median OS from registration has not been reached. Median OS for poor risk subjects = 7.9 months. Median OS for intermediate risk subjects has yet to be reached, but will exceed 28.3+ months. Conclusions: AGS-003 is well tolerated with no immunotherapy-related SAEs or grade 3/4 AEs reported. Interim data indicate that AGS-003 in combination with sunitinib yields a median OS higher than that reported for sunitinib alone in unfavorable risk subjects. Updated OS and immune response correlates will be presented. These results support the ongoing, randomized phase III ADAPT study.
8
Anisah, Anisah. "PENERAPAN METODE PEMBERIAN TUGAS UNTUK MENINGKATKAN KEMANDIRIAN ANAK USIA 5-6 TAHUN DI TK SATU ATAP SDN 003 SIHEPENG TAHUN AJARAN 2016/2017." Jurnal Guru Kita PGSD 2, no. 1 (August 11, 2018): 137. http://dx.doi.org/10.24114/jgk.v2i1.10465.
Full textAbstract:
Abstrak: Penerapan Metode Pemberian Tugas untuk MeningkatkanKemandirian Anak Usia 5-6 Tahun di TK Satu Atap SDN 003 Sihepeng TahunAjaran 2016/2017. Tujuan penelitian ini adalah untuk meningkatkan kemandirianpada anak usia 5-6 tahun melalui penggunaan metode pemberian tugas di TK SatuAtap SDN 003 SihepengTahun Ajaran 2016/2017. Jenis penelitian yang digunakanpenulis adalah jenis PTK (Penelitian Tindakan Kelas). Penelitian ini dilakukan diTK Satu Atap SDN 003 SihepengSihepeng, Kecamatan Siabu KabupatenMandailing Natal Tahun Ajaran 2016/2017 dan waktu penelitian selama 4 bulan (bulanMaret 2017 - Juni 2017. Subjek penelitian ini adalah anak usia 5-6 tahun TKSatu Atap SDN 003 Sihepeng berjumlah 22 orang pada tahun ajaran 2016/2017.Sedangkan objek penelitian adalah meningkatkan kemandirian anak usia 5-6 tahundi TK Satu Atap SDN 003 TA 2016/2017. Hasil penelitian yang diperoleh yaitumetode pemberian tugas dapat meningkatkan kemandirian anak usia 5-6 tahun di TKSatu Atap SDN 003 Sihepeng T.A 2016/2017.Kata Kunci : Metode Pemberian Tugas, Kemandirian Anak
9
Barua, H., M. H. Rahman, M. M. Alam Patwary, M. Zahirul Alam, and S. Nahar. "Variations in Growth and Yield of Indigenous Hyacinth Bean (Lablab purpureus (L.) Sweet) Genotypes." Agriculturists 12, no. 2 (January 25, 2015): 01–05. http://dx.doi.org/10.3329/agric.v12i2.21724.
Full textAbstract:
Variations in growth and yield of three hyacinth bean genotypes collected from Sitakundu of Chittagong, were investigated at the Agricultural Research Station (ARS) of Bangladesh Agricultural Research Institute (BARI), Pahartali, Chittagong during November 2011 to March 2012, where BARI Seem-4 was used as standard control. The minimum number of days for pod formation (54 days) was recorded in BARI Seem-4, while the maximum was in DLP 002 (62 days). The highest number of pods (324) per plant was obtained from DLP 001 followed by DLP 003 (212.33) and the lowest (148.33) was obtained from BARI Seem-4. The maximum weight (12.61 g) of single pod was observed in DLP 003, which is close to that of DLP 002 (12.23 g). The minimum weight of single pod (7.08g) was however observed in DLP 001. Weight of 100-green seed (117.17 g) was maximum in DLP 002, while that of DLP 001 was the minimum (85.90 g).The maximum green seed (61.86 %) was found in DLP 003 and the minimum was in DLP 001 (47.89 %). DLP 003 produced the highest pod yield (26.77 t/ha) which was followed by DLP 001 (22.94 t/ha), while BARI Seem-4 produced the lowest (17.43 t/ha), which is close to that of DLP 002 (19.57 t/ha).The Agriculturists 2014; 12(2) 01-05
10
Mustika, Dea, Amisha Dewinta Amama, Aisyah Fitriani, Amelin Fahesa, Alvitta Tiara, Siti Quratul Ain, Leny Julia Lingga, and Deswalila Amanda. "Sosialisasi Program Kegiatan Kampus Mengajar Angkatan 4 di SD 003 YKWI Pekanbaru." Joong-Ki : Jurnal Pengabdian Masyarakat 2, no. 2 (May 23, 2023): 428–33. http://dx.doi.org/10.56799/joongki.v2i2.1720.
Full textAbstract:
Kampus mengajar merupakan bagian dari program Merdeka Belajar Kampus Merdeka. Kegiatan sosialisasi didasari karena dibutuhkannya kesepakatan program kegiatan kampus mengajar untuk dapat dilaksanakan di sekolah sasaran. Sosialisasi dilakukan dengan metode diskusi dan presentasi dengan tiga tahapan yaitu persiapan, sosialisasi kegiatan dan rencana tindak lanjut. Hasil kegiatan sosialisasi mendapatkan temuan bahwa pihak sekolah menerima dengan terbuka kedatangan tim kampus mengajar serta menunjukkan sikap antusias terhadap rencana program yang mahasiswa sampaikan. Harapan yang disampaikan oleh pihak sekolah agar program kampus mengajar dapat menjadi program berkelanjutan demi membantu meningkatkan mutu dan kualitas pembelajaran di sekolah-sekolah sasaran.
11
Marsixtin, Marsixtin. "MENINGKATKAN PERILAKU AKTIFITAS DAN HASIL BELAJAR IPA MELALUI MODEL KOOPERATIF TIPE STAD SISWA KELAS VI SD NEGERI 003 PULAU PERMAI KECAMATAN TAMBANG KABUPATEN KAMPAR." JURNAL PAJAR (Pendidikan dan Pengajaran) 3, no. 1 (January 31, 2019): 133. http://dx.doi.org/10.33578/pjr.v3i1.6438.
Full textAbstract:
Penelitian ini bertujuan untuk meningkatkan perilaku aktivitas dan hasil belajar IPA melalui model kooperatif tipe STAD terhadap siswa kelas VI SD Negeri 003 Pulau Permai Kecamatan Tambang Kabupaten Kampar. Rumusan masalah dalam penelitian ini adalah “Apakah penggunaan model kooperatif tipe STAD dapat meningkatkan perilaku aktifitas dan hasil belajar IPA siswa kelas VI SD Negeri 003 Pulau PermaiKecamatan Tambang Kabupaten Kampar. Subjek dalam penelitian ini adalah siswa kelas VI SD Negeri 003 Pulau Permai yang berjumlah 34 siswa, yaitu 18 orang siswa laki-laki dan 16 orang siswa perempuan.Penelitian ini terdiri atasII siklus dan 4 kali pertemuan. Setiap pertemuan terdiri atas 4 tindakan, yaitu: perencanaan, tindakan, observasi dan penilaian, dan refleksi. Hasil penelitian menunjukkan bahwa data perilaku aktivitas belajar siswa pada siklus I dengan kategori amat baik 37,50% dan siklus II yang berkategori amat baik 81,25%. Dengan demikian terjadi peningkatan 43.75%. Untuk hasil belajar pada siklus I, rata-rata yang tuntas 75,29% dan siklus II 96,48%. Dengan demikian terjadi peningkatan 21,19%.Berdasarkan hasil penelitian dapat disimpulkan bahwa penggunaan kooperatif tipe STAD dapat meningkatkan perilaku aktivitas dan hasil belajar IPA siswa kelas VI SD Negeri 003 Pulau Permai Kecamatan Tambang Kabupaten Kampar.
12
Tricou, Vianney, Brandon Essink, John E. Ervin, Mark Turner, Ian Escudero, Martina Rauscher, Manja Brose, Inge Lefevre, Astrid Borkowski, and Derek Wallace. "Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study." PLOS Neglected Tropical Diseases 17, no. 3 (March 8, 2023): e0011124. http://dx.doi.org/10.1371/journal.pntd.0011124.
Full textAbstract:
Background Yellow fever (YF) vaccination is often mandatory for travelers to YF-endemic areas. The areas with risk of YF partially overlap with those of dengue, for which there is currently no recommended vaccine available for dengue-naïve individuals. This phase 3 study assessed the immunogenicity and safety of concomitant and sequential administration of YF (YF-17D) and tetravalent dengue (TAK-003) vaccines in healthy adults aged 18–60 years living in areas of the US non-endemic for either virus. Methods Participants were randomized 1:1:1 to receive the following vaccinations at Months 0, 3, and 6, respectively: YF-17D+placebo, TAK-003, and TAK-003 (Group 1); TAK-003+placebo, TAK-003, and YF-17D (Group 2); or YF-17D+TAK-003, TAK-003, and placebo (Group 3). The primary objective was to demonstrate non-inferiority (upper bound of 95% confidence interval [UB95%CI] of difference <5%) of YF seroprotection rate one month following concomitant administration of YF-17D and TAK-003 (Group 3) compared with YF-17D plus placebo (Group 1). The secondary objectives included demonstration of non-inferiority of YF and dengue geometric mean titers (GMTs) (UB95%CI for GMT ratio <2.0), and safety. Results 900 adults were randomized. YF seroprotection rates one month post-YF-17D (Month 1) were 99.5% and 99.1% in Group 1 and 3, respectively, and non-inferiority was demonstrated (UB95%CI = 2.69% i.e. <5%). Non-inferiority was also demonstrated for GMTs against YF one month post-YF-17D, and against DENV-2, -3, and -4 (UB95%CI <2), but not DENV-1 (UB95%CI: 2.22), one month post-second TAK-003 vaccination. Adverse event rates following TAK-003 were consistent with previous results, and no important safety risks were identified. Conclusions In this study, YF-17D vaccine and TAK-003 were immunogenic and well tolerated when sequentially or concomitantly administered. The non-inferiority of immune responses to YF-17D and TAK-003 was demonstrated for concomitant administration of the 2 vaccines compared to separate vaccination, except against DENV-1 but with GMTs similar to those observed in other TAK-003 trials. Trial registration ClinicalTrials.gov identified: NCT03342898.
13
Dharmarajan, A., N. Zeps, and S. McLaren. "003.Expression of secreted frizzled related protein-4 (sFRP-4) and associated Wnt signalling in cancer and apoptosis." Reproduction, Fertility and Development 17, no. 9 (2005): 63. http://dx.doi.org/10.1071/srb05abs003.
Full textAbstract:
We examined the interplay between Wnt and secreted frizzled related protein-4 (sFRP4) in estradiol induced cell growth in breast cancer cells (MCF-7), and also determined the in vivo distribution of sFRP-4 in human breast cancer. MCF-7 cells were treated with estradiol, sFRP-4 conditioned media and a combination of the two. Real-time RT-PCR and Western blot analysis were used to determine the expression of the sFRP-4 and its associated Wnt signalling molecules following treatment. Immunohistochemistry was performed to examine sFRP-4 expression patterns in human breast cancers. Estradiol treatment up-regulated the expression of the Wnt signalling genes Wnt-10b, beta-catenin and fz-4 (P < 0.001 for all genes). This up-regulation was not associated with an increase in the Wnt signalling pathway as measured by the levels of active beta-catenin. sFRP-4 conditioned media reduced MCF-7 cell proliferation, down-regulated the Wnt signalling genes beta-catenin and fz-4 as well as down-regulating wnt signalling activity. sFRP-4 was able to reduce the proliferation of estradiol stimulated MCF-7 cells. Cytoplasmic sFRP-4 protein was expressed in all breast tumours examined, with intense staining evident in the lobular carcinoma in situ and the ductal carcinoma. These data demonstrate that sFRP-4 is a potent inhibitor of the Wnt signalling pathway in MCF-7 cells, acting not only to down-regulate the activity of the wnt signalling pathway, but also down-regulate the transcription of Wnt signalling genes. The results of these in vitro and immunohistochemical experiments warrant further investigation as to whether sFRP-4 expression can be indicative of prognosis in human breast cancer. In addition to breast cancer, we have also examined the role of sFRP-4 in other cancers such as ovarian and prostate.
14
Fristika, Yessy Octa. "GAMBARAN PENGETAHUAN DAN SIKAP IBU TENTANG GERAKAN 1000 HARI PERTAMA KEHIDUPAN." JURNAL KESEHATAN INDRA HUSADA 9, no. 2 (December 27, 2021): 33–42. http://dx.doi.org/10.36973/jkih.v9i2.321.
Full textAbstract:
1000 Hari Pertama Kehidupan adalah periode percepatan tumbuh kembang yang dimulai sejak terbentuknya janin dalam kandungan hingga anak berusia 2 tahun. Pada periode tersebut, terjadi perkembangan otak, pertumbuhan badan, perkembangan sistem metabolisme tubuh dan pembentukan sistem kekebalan tubuh yang begitu cepat. Penelitian ini bertujuan untuk melihat Gambaran Pengetahuan dan Sikap Ibu tentang Gerakan 1000 Hari Pertama Kehidupan di RT.003 RW.003 Tanjung Bubuk, Kel. Bukit Baru, Kec. Ilir Barat I Palembang Tahun 2020. Penelitian ini menggunakan desain deskriptif dengan pendekatan cross sectional. Analisa yang digunakan adalah univariat. Sampel penelitian yang diambil secara purposive sampling. jumlah sampel dalam penelitian ini adalah berjumlah 20 orang sampel. Berdasarkan penelitian pengetahuan bahwa sebagian besar ibu memiliki pengetahuan yang tidak baik yaitu 16 orang (80%) dan ibu yang memiliki pengetahuan yang baik yaitu 4 orang (20%). Berdasarkan sikap bahwa sikap ibu terhadap gerakan 1000 hari pertama kehidupan memiliki sikap tidak baik sebanyak 12 orang (60%) dan sikap ibu yang baik sebanyak 8 orang (40%). Hasil penelitian ini merekomendasikan kepada Ketua RT.003 RW.003 dan masyarakat di RT.003 RW.003 untuk meningkatkan informasi tentang kesehatan khususnya tentang gerakan 1000 Hari Pertama Kehidupan. Rekomendasi ini juga diberikan untuk para peneliti lain yang bermaksud mengadakan penelitian tentang gerakan 1000 HPK agar melibatkan lebih banyak sampel dan variabel yang diteliti dengan desain yang berbeda serta menggunakan instrument yang telah memiliki nilai validitas dan reliabilitas baku.
15
Debataraja, Mularingan. "Peningkatan Keterampilan Membaca Gagasan Paragraf melalui Pendekatan Keterampilan Proses dan Teknik Tugas Menyalin Pemaknaan Leksikal." Jurnal Pembelajaran Bahasa dan Sastra 2, no. 3 (May 1, 2023): 391–400. http://dx.doi.org/10.55909/jpbs.v2i3.285.
Full textAbstract:
Penelitian tindakan kelas ini bertujuan untuk meningkatkan: 1) prosedur pelaksanaan pembelajaran keterampilan menemukan gagasan paragraf sederhana melalui pendekatan keterampilan proses dan teknik tugas menyalin pemaknaan leksikal; 2) besaran tuntas keterampilan menemukan gagasan paragraf sederhana melalui pendekatan keterampilan proses dan teknik tugas menyalin pemaknaan leksikal. Penelitian dilakukan pada awal semester genap tahun ajaran 2022-2023 di kelas 4 SD Negeri 003 Pulau Kijang, Kecamatan Reteh, Kabupaten Indragiri Hilir, Provinsi Riau. Subjek penelitian adalah 16 dari 24 siswa kelas 4 yang belum mencapai KKM 70,00 pada pembelajaran reguler. Instrumen penelitian: 1) tes objektif tentang menemukan gagasan bacaan melalui pemaknaan leksikal yang valid dan reliabel; 2) LKPD yang berisi tutnjuk ajar tentang menemukan gagasan bacaan melalui pemaknaan leksikal dan berisi deskripsi tentang kosa kata yang dilengkapi dengan akti leksikal yakni arti menurut Kamus Besar Bahasa Indonesia; 3) RPP; 4) pedoman observasi kegiatan guru dan kegiatan siswa; 5) alat rekam untuk digunakan di prosedur pelaksanaan dan observasi. Data hasil belajar dikumpulkan menggunakan instrumen tes pilihan ganda sedangkan data prosedur pembelajaran dikumpulkan menggunakan tekni rekaman dari HP. Analisis data keterampilan menemukan gagasan bacaan menggunakan statistik deskriptif dan data prosedur pembelajaran dianalisis secara tematik. Hasil penelitian: 1) jumlah siswa kelas 4 SD Negeri 003 Pulau Kijang yang tuntas dalam pembelajaran di siklus pertama sebanyak 9 dari 16 siswa atau 56,25; 2) jumlah siswa kelas 4 SD Negeri 003 Pulau Kijang yang tuntas dalam pembelajaran di siklus kedua sebanyak 6 dari 7 siswa atau 85,71.
16
White, Laura J., Ellen F. Young, Mark J. Stoops, Sandra R. Henein, Elizabeth C. Adams, Ralph S. Baric, and Aravinda M. de Silva. "Defining levels of dengue virus serotype-specific neutralizing antibodies induced by a live attenuated tetravalent dengue vaccine (TAK-003)." PLOS Neglected Tropical Diseases 15, no. 3 (March 12, 2021): e0009258. http://dx.doi.org/10.1371/journal.pntd.0009258.
Full textAbstract:
The four dengue virus serotypes (DENV1-4) infect several hundred million people each year living in tropical and sub-tropical regions. Clinical development of DENV vaccines is difficult because immunity to a single serotype increases risk of severe disease during a second infection with a new serotype. Leading vaccines are based on tetravalent formulations to induce simultaneous and balanced protective immunity to all 4 serotypes. TAK-003 is a tetravalent live attenuated dengue vaccine candidate developed by Takeda Vaccines Inc, which is currently being evaluated in phase 3 efficacy trials. Here, we use antibody depletion methods and chimeric, epitope transplant DENVs to characterize the specificity of neutralizing antibodies in dengue-naïve adults and non-human primates immunized with TAK-003. Our results demonstrate that TAK-003 induced high levels of DENV2 neutralizing antibodies that recognized unique (type-specific) epitopes on DENV2. In contrast, most vaccinated subjects developed lower levels of DENV1, DENV3 and DENV4 neutralizing antibodies that mainly targeted epitopes that were conserved (cross-reactive) between serotypes. Trial Registration: ClinicalTrials.gov NCT02425098.
17
Menéndez, R., R. Más, J. Pérez, R. M. González, and S. Jiménez. "Oral administration of D-003, a mixture of very long chain fatty acids prevents casein-induced endogenous hypercholesterolemia in rabbits." Canadian Journal of Physiology and Pharmacology 82, no. 1 (January 1, 2004): 22–29. http://dx.doi.org/10.1139/y03-123.
Full textAbstract:
D-003 is a mixture of very long chain saturated fatty acids (VLCSFA) purified from sugar cane wax with cholesterol-lowering effects proven in animal models and healthy volunteers. D-003 inhibits cholesterol biosynthesis through the regulation of HMG-CoA reductase activity. Rabbits fed diets enriched with casein develop endogenous hypercholesterolemia (EH), making them a very useful model for determining the mechanism of action of drugs affecting lipids. We examined whether D-003 prevented EH. Rabbits were fed a casein diet for 4 weeks, administered simultaneously with D-003 (5, 50, and 100 mg·kg–1·day–1). As expected, nontreated rabbits became hipercholesterolemic; however, as early as 15 days following administration, the treated group (50 and 100 mg·kg–1·day–1) had significantly decreased total cholesterol and low-density lipoprotein cholesterol (LDL-C). Triglycerides were not affected; however, at study completion, HDL-C levels significantly increased at all the doses assayed. D-003 inhibited de novo synthesis of cholesterol, since the incorporation of 3H2O into sterols in the liver and proximal small bowel was significantly depressed. Also, D-003 significantly raised the rate of removal of [125I]-LDL from serum and significantly elevated [125I]-LDL binding activity to liver homogenates. Taken together, these results show that the efficacy of D-003 in reducing casein-derived hypercholesteromeia could involve, at least partially, an inhibition of hepatic cholesterol bio synthesis, which may elicit a decreased cholesterol concentration in hepatocytes, preventing the loss of hepatic LDL receptors induced by casein administration. However, since casein-induced hypercholesterolemia is also a consequence of a stimulation of cholesterol absorption in the lumen and an increase of the output of cholesterol associated with LDL, the effect of D-003 on cholesterol absorption and LDL synthesis by the liver should be investigated.Key words: D-003, very long chain saturated fatty acids, casein-fed rabbits, LDL-C, cholesterol biosynthesis, LDL clearance, LDL receptor.
18
Beeharry, Neil, Sean Landrette, Jeff Grotzke, Sophia Gayle, Marylens Hernandez, Stephanie Halene, Peter R. Young, et al. "LAM-003, a Novel Oral Heat Shock Protein 90 Inhibitor for Treatment of Acute Myeloid Leukemia, Including Wild-Type and FMS-like Tyrosine Kinase 3 (FLT3)-Mutant Disease." Blood 134, Supplement_1 (November 13, 2019): 2664. http://dx.doi.org/10.1182/blood-2019-125770.
Full textAbstract:
Acute myeloid leukemia (AML) remains a disease with high unmet medical need. While most patients respond to initial therapy, few are cured, relapse rates are high, and most patients eventually develop life-threatening complications. FLT3-mutant disease is a particularly aggressive subtype. Recent approval of drugs targeting FLT3-mutant disease have improved short-term outcomes but not all patients respond, and duration of response is limited by secondary mutations that impede FLT3 inhibitor (FLT3i) binding (intrinsic factors) and by secreted stromal factors that activate alternative pro-survival pathways (extrinsic factors). Heat-shock protein 90 (HSP90) is a chaperone protein involved in many cellular processes and inhibition of HSP90 can have pleiotropic effects in targeting cancer cells such as degradation of oncoproteins that drive survival and proteins that mediate protective signaling. Here, we describe the nonclinical activity of LAM-003, an orally bioavailable HSP90 inhibitor (HSP90i) under clinical development for AML. To assess the anti-leukemic activity of LAM-003, we tested a panel of AML cell lines and primary AML samples. LAM-003 inhibited proliferation of both FLT3-mutant and wild-type cell lines, with preferential activity against cells harboring FLT3-ITD (geometric mean FLT3-ITD EC50 = 670 nM [n=8] vs FLT3 WT EC50 = 1400 nM [n=16]). Additionally, we observed that LAM-003 was potent in a subset of the FLT3 WT cells. To explore whether LAM-003 was effective against tumors driven by oncoproteins that are client proteins of HSP90, we focused on AML cells harboring FLT3-ITD. We confirmed that LAM-003 reduced cell surface FLT3-ITD expression and downstream signaling in MV-4-11 and MOLM-13 cells, consistent with HSP90i-mediated degradation of FLT3-ITD. In BA/F3 cells expressing FLT3-ITD with various secondary resistance mutations, we observed that LAM-003 elicited a dose-dependent reduction of FLT3 mutant cell surface expression. Moreover, BA/F3 cells expressing FLT3-ITD and the F691L mutation exhibited the expected resistance to crenolanib, yet LAM-003 retained anti-proliferative activity. Additionally, MOLM-13 cells harboring a FLT3 D835Y mutation demonstrated expected resistance to the FLT3i sorafenib and tandutinib yet remained sensitive to LAM-003. Finally, primary AML blasts harboring a D835 mutation displayed sensitivity to LAM-003 when tested ex vivo. To evaluate the potential of LAM-003 to overcome bone-marrow-stroma-derived resistance, FLT3-ITD AML cell lines (MV-4-11, MOLM-13, MOLM-14) were assayed in unconditioned or stromal-cell-conditioned medium. Conditioned medium dramatically reduced the potency of FLT3i but LAM-003 demonstrated equal potency under both conditions. We also showed that stromal cell co-culture induced FLT3i resistance in MOLM-13 cells whereas LAM-003 retained potent activity. Recognizing that the inherent genetic heterogeneity of AML blasts limits the curative potential of a single drug, we performed in vitro studies to identify drugs that synergize with LAM-003 in 3 FLT3-ITD AML cell lines. Synergy was demonstrated with FLT3i, daunorubicin, azacitidine or cytarabine, with the most robust synergy being observed with venetoclax. Extending the evaluation to AML cells wild type for FLT3 and cell lines from other hematologic indications (multiple myeloma, diffuse large B-cell lymphoma and mantle cell lymphoma), we found that the synergy was not limited to cells harboring FLT3-ITD, but rather correlated with BCL-2 abundance, suggesting a fundamental mechanism of action that depends on BCL-2 family-mediated survival. Mechanistic studies demonstrated that the combination of LAM-003 and venetoclax inhibited AKT-mediated regulation of GSK3B, resulting in MCL-1 degradation. In vivo studies using a MOLM-13 systemic model of FLT3-ITD AML demonstrated that LAM-003 monotherapy significantly improved animal survival and that the combination of LAM-003 and venetoclax significantly prolonged animal survival compared with each single agent. These nonclinical studies demonstrate that LAM-003 exhibits antileukemic activity, overcomes mechanisms of FLT3i resistance and potently synergizes with existing AML drugs. As such, our data provide strong rationale for evaluation of LAM-003 in an ongoing clinical trial in patients with AML (NCT03426605). Disclosures Beeharry: AI Therapeutics: Employment, Equity Ownership. Landrette:AI Therapeutics: Employment. Grotzke:AI Therapeutics: Employment. Gayle:AI Therapeutics: Equity Ownership. Young:AI Therapeutics: Employment, Equity Ownership. Miller:Incuron, Inc.: Consultancy; Cleveland Biolabs, Inc: Employment, Equity Ownership; Calistoga Pharmaceuticals, Inc.: Equity Ownership; AI Therapeutics: Consultancy, Equity Ownership; VelosBio Inc.: Employment, Equity Ownership; Acerta Pharma, Inc.: Equity Ownership. Xu:AI Therapeutics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees. Rothberg:AI Therapeutics: Equity Ownership, Membership on an entity's Board of Directors or advisory committees. Lichenstein:AI Therapeutics: Employment, Equity Ownership.
19
Sharma, Mayuri, Dustin R. Glasner, Heather Watkins, Henry Puerta-Guardo, Yoseph Kassa, Michael A. Egan, Hansi Dean, and Eva Harris. "Magnitude and Functionality of the NS1-Specific Antibody Response Elicited by a Live-Attenuated Tetravalent Dengue Vaccine Candidate." Journal of Infectious Diseases 221, no. 6 (February 19, 2019): 867–77. http://dx.doi.org/10.1093/infdis/jiz081.
Full textAbstract:
Abstract Background Dengue virus (DENV) can cause life-threatening disease characterized by endothelial dysfunction and vascular leakage. DENV nonstructural protein 1 (NS1) induces human endothelial hyperpermeability and vascular leak in mice, and NS1 vaccination confers antibody-mediated protective immunity. We evaluated the magnitude, cross-reactivity, and functionality of NS1-specific IgG antibody responses in sera from a phase 2 clinical trial of Takeda’s live-attenuated tetravalent dengue vaccine candidate (TAK-003). Methods We developed an enzyme-linked immunosorbent assay to measure anti-DENV NS1 IgG in sera from DENV-naive or preimmune subjects pre- and postvaccination with TAK-003 and evaluated the functionality of this response using in vitro models of endothelial permeability. Results TAK-003 significantly increased DENV-2 NS1-specific IgG in naive individuals, which cross-reacted with DENV-1, -3, and -4 NS1 to varying extents. NS1-induced endothelial hyperpermeability was unaffected by prevaccination serum from naive subjects but was variably inhibited by serum from preimmune subjects. After TAK-003 vaccination, all samples from naive and preimmune vaccinees completely abrogated DENV-2 NS1-induced hyperpermeability and cross-inhibited hyperpermeability induced by DENV-1, -3, and -4 NS1. Inhibition of NS1-induced hyperpermeability correlated with NS1-specific IgG concentrations. Postvaccination sera also prevented NS1-induced degradation of endothelial glycocalyx components. Conclusion We provide evidence for functional NS1-specific IgG responses elicited by a candidate dengue vaccine. Clinical Trials Registration NCT01511250.
20
Hranov, G., and N. A. Fineberg. "P.4.a.003 Are tics an essential symptom of the obsessive-compulsive syndrome?" European Neuropsychopharmacology 20 (August 2010): S521—S522. http://dx.doi.org/10.1016/s0924-977x(10)70780-x.
Full text
21
Luigjes, J., M. Figee, P. N. Tobler, W. Van den Brink, B. De Kwaasteniet, G. Van Wingen, and D. Denys. "P.4.b.003 Doubt in the insula: risk processing in obsessive–compulsive disorder." European Neuropsychopharmacology 24 (October 2014): S588—S589. http://dx.doi.org/10.1016/s0924-977x(14)70943-5.
Full text
22
Park, J. E., and J. Choi. "P.4.c.003 Fluoxetine effect on neuronal differentiation in human embryonic carcinoma cells." European Neuropsychopharmacology 25 (September 2015): S564. http://dx.doi.org/10.1016/s0924-977x(15)30788-4.
Full text
23
Panigada, F., L. Liperi, F. F. Siliprandi, G. Blaser, M. Locatelli, E. Smeraldi, and C. Insacco. "P.4.a.003 Aripiprazole augmentation of fluvoxamine in poor-insight obsessive-compulsive patients." European Neuropsychopharmacology 16 (January 2006): S450. http://dx.doi.org/10.1016/s0924-977x(06)70585-5.
Full text
24
Alacio, Rosa Ynés. "Reseña: Estragos y Limitaciones de la Democracia Interna, Universidad Autónoma de Chihuahua- Sindicato del Personal Académico de la Universidad Autónoma de Chihuahua, México, 212 pp . ISBN 978-607-536-003-4." Revista Mexicana de Estudios Electorales 4, no. 23 (2020): 203–6. http://dx.doi.org/10.54505/somee.rmee.2020.4.23.a8.
Full textAbstract:
Sarabia Ríos, Cecilia (2017), Estragos y Limitaciones de la Democracia Interna, Universidad Autónoma de Chihuahua- Sindicato del Personal Académico de la Universidad Autónoma de Chihuahua, México, pp. 212. ISBN 978-607-536-003-4.
25
Soldevila i Balart, Llorenç. "Daniel P. Grau, «El dit sobre el mapa. Joan Fuster i la descripció del territori», València, Publicacions de la Universitat de València, 2017, 409 p." Caplletra. Revista Internacional de Filologia, no. 67 (October 16, 2019): 215. http://dx.doi.org/10.7203/caplletra.67.15404.
Full textAbstract:
Ressenya sobre el llibre de Daniel P. Grau, El dit sobre el mapa. Joan Fuster i la descripció del territori, València, Publicacions de la Universitat de València, 2017, 409 p., ISBN: 978-84-9134-003-4.
26
Omidi, Nazanin, Kaitlin Victor, Lauren Gray, Iqra Nadeem, Jessica Bolton, Tanisha Robinson, Kristin Hatch, et al. "Analysis of T Cell Immunity Generated by Takeda’s Tetravalent Dengue Vaccine." Journal of Immunology 210, no. 1_Supplement (May 1, 2023): 246.10. http://dx.doi.org/10.4049/jimmunol.210.supp.246.10.
Full textAbstract:
Abstract Dengue is a viral disease transmitted to humans through the bite of infected mosquitoes and is caused by dengue virus (DENV), which has four distinct serotypes, DENV1 to DENV4. Severe dengue is a leading cause of serious illness and death in some Asian and Latin American countries. The Walter Reed Army Institute of Research (WRAIR) has been working to investigate the cell mediated immunogenicity of Takeda’s live attenuated virus tetravalent dengue vaccine (TAK-003). Previously, we have used ELISPOT and Flow-ICS assays to show that TAK-003 induces a robust IFN-γ producing DENV-specific T cell response that is durable to at least 6 months post-vaccination. In addition, this response is mediated by both CD8+ and CD4+ T cells that produce IFN-γ and/or TNFα and IL-2. Using samples from a phase II study, DEN-313 (NCT02948829) conducted in healthy children aged 4 to 16 years in dengue endemic locations, herewith we extend the findings on TAK-003 induced DENV-specific T cell responses to: (1) present data on durability of the CMI response through 3 years post-vaccination; (2) verify the serotype coverage of the T cell response; (3) assess multifunctional capacity of the durable memory T cells, and (4) describe the phenotypic changes that occur among these cells based upon central memory (CD45RA−/CCR7+), effector memory (CD45RA−/CCR7−) and effector memory RA phenotyping (CD45RA+/CCR7−). Our data describe the frequency, functionality, and memory phenotype of T cells induced by TAK-003 up to 3 years post vaccination. Finding received through corporative research and development agreement with Takeda vaccine company.
27
Trudel, Suzanne, Susan Lee, Christopher J. Kirk, Nashat Gabrail, Sagar Lonial, Luhua Wang, Robert Z. Orlowski, et al. "Inhibition of the Proteasome in Bone Marrow-Derived CD138+ Tumor Cells Following Carfilzomib Administration in Relapsed or Refractory Myeloma Patients." Blood 114, no. 22 (November 20, 2009): 1845. http://dx.doi.org/10.1182/blood.v114.22.1845.1845.
Full textAbstract:
Abstract Abstract 1845 Poster Board I-871 Background: Proteasome inhibition is an effective strategy for the treatment of multiple myeloma. In patients, proteasome inhibition has primarily been measured in peripheral blood samples (whole blood or mononuclear cells). However, it is unknown whether myeloma cells in the bone marrow (BM) are equally sensitive to proteasome inhibitors such as bortezomib (BTZ) and carfilzomib (CFZ). Aim: To measure proteasome inhibition in purified tumor cells from BM samples taken from patients enrolled in two ongoing Phase 2 trials of single agent CFZ in relapsed or refractory myeloma: PX-171-003 (003) and PX-171-004 (004). Methods: CFZ was administered as an IV bolus of 20 mg/m2 on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle on both trials. Bone marrow samples, from an optional sub-study of both trials, were taken during screening and Day 2 (post-treatment) and sorted into CD138+ and CD138− cells. Proteasome activity was measured by an enzymatic assay using a fluorogenic substrate (LLVY-AMC) for the chymotrypsin-like (CT-L) activity and an active site ELISA (ProCISE) to quantitate levels of the CT-L subunits of the constitutive proteasome (Beta5) and immunoproteasome (LMP7) and the immunoproteasome subunit MECL1. Results: Whole blood samples from patients treated with CFZ showed inhibition of CT-L activity of ∼80+, similar to values obtained in Phase 1 studies. A total of 10 CD138+ screening samples, 6 from 004 and 4 from 003, and 9 post-dose samples, 5 from 004 and 4 from 003, were analyzed for proteasome levels and activity. In addition, 15 CD138−screening samples, 7 from 004 and 8 from 003, and 9 post-dose samples, 5 from 004 and 4 from 003, were analyzed. When compared to the average base-line activity, CFZ treatment resulted in 88% CT-L inhibition in CD-138+tumor cells from 004 patients (P = 0.0212 by unpaired t-test) and 59% CT-L inhibition in CD-138+ tumor cells from 003 patients (P = 0.25). Baseline CT-L activity in CD138+ tumor cells was 3-fold higher in 004 than 003, which includes a more heavily pre-treated patient population with greater prior exposure to BTZ. Higher specific enzymatic activity was due to increased levels of both constitutive and immunoproteasomes in tumor cells, where immunoproteasomes account for >75% of total cellular proteasomes. No differences between trials were seen in baseline CT-L activity from non-tumor (CD138−) cells. Inhibition in CD138− cells was 84% (P = 0.0380 and 42% (P = 0.38) in 004 and 003, respectively. Using ProCISE, we measured inhibition of LMP7 (66%), beta5 (48%) and MECL1 (64%) in CD138+ tumor cells from 004 patients. Three patients from 004 and one from 003 had both a screening and post-dose tumor cell samples available for analysis. Inhibition of CT-L activity was >80% in two of the 3 patients on 004; the third patient showed no proteasome inhibition by ProCISE and was unavailable for analysis by CT-L. CT-L activity in the CD138+ tumor cells in the 003 patient was not inhibited, however, inhibition was seen in non-tumor cells. Conclusions: CFZ inhibits the proteasome activity of myeloma cells in the bone marrow of relapsed and refractory myeloma patients. The levels of inhibition were similar to those measured in whole blood samples, supporting the use of the blood-based assay as a surrogate marker for proteasome inhibition in tumor cells. CFZ treatment resulted in inhibition of both CT-L subunits as well as additional subunits of the immunoproteasome in tumor cells. Reduced baseline activity in the more heavily pretreated 003 patients may reflect reduced tumor-dependency on the proteasome and may be related to prior treatment with BTZ in these patients. More samples are needed in order to make correlations between levels of proteasome inhibition in bone marrow tumor cells and prior therapies or response. These observations support further evaluation of proteasome activity and the effects of this promising new agent in primary tumors cells from myeloma patients. Disclosures: Trudel: Celgene: Honoraria, Speakers Bureau; Ortho Biotech: Honoraria. Lee:Proteolix, Inc.: Employment. Kirk:Proteolix, Inc.: Employment. Lonial:Celgene: Consultancy; Millennium: Consultancy, Research Funding; BMS: Consultancy; Novartis: Consultancy; Gloucester: Research Funding. Wang:Proteolix, Inc.: Research Funding. Kukreti:Celgene: Honoraria. Stewart:Genzyme, Celgene, Millenium, Proteolix: Honoraria; Takeda, Millenium: Research Funding; Takeda-Millenium, Celgene, Novartis, Amgen: Consultancy. Jagannath:Millennium: Honoraria, Membership on an entity's Board of Directors or advisory committees; Merck: Honoraria, Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees. McDonagh:Proteolix: Research Funding. Zonder:Celgene: Speakers Bureau; Pfizer: Consultancy; Seattle Genetics, Inc.: Research Funding; Amgen: Consultancy; Millennium: Research Funding. Bennett:Proteolix: Employment.
28
Lipkin, Sanna. "Gavin Lucas: Archaeological Situations: Archaeological Theory from the Inside Out. Routledge, 2023." Fennoscandia Archaeologica, no. XL (December 15, 2023): 139–40. http://dx.doi.org/10.61258/fa.141668.
Full textAbstract:
Gavin Lucas. Archaeological Situations: Archaeological Theory from the Inside Out. Routledge, 2023. ISBN 978-0-367-56545-9 (hbk), ISBN 978-0-367-56010-2 (pbk), ISBN 978-1-003-09829-4 (ebk) 208 pp. https://doi.org/10.4324/9781003098294
29
Lee, S. J., H. D. Rim, S. R. Kim, J. H. Lee, S. M. Chang, E. Seo, U. S. Chung, S. H. Jeong, and B. J. Kang. "P.4.a.003 The characteristics of salivary alpha-amylase reactivity to negative affective pictures." European Neuropsychopharmacology 18 (August 2008): S479. http://dx.doi.org/10.1016/s0924-977x(08)70714-4.
Full text
30
Yoon, H. K., Y. K. Kim, and B. H. Lee. "P.4.b.003 Effect of a tryptophan hydroxylase 2 gene polymorphism on panic disorder." European Neuropsychopharmacology 18 (August 2008): S488. http://dx.doi.org/10.1016/s0924-977x(08)70729-6.
Full text
31
Audi, E. A., C. Biesdorf, and D. A. G. Cortez. "P.4.b.003 Anxiolytic and panicolytic effects of a standardized fraction from Kielmeyera coriacea." European Neuropsychopharmacology 21 (September 2011): S533—S534. http://dx.doi.org/10.1016/s0924-977x(11)70868-9.
Full text
32
Oh, K. S., S. J. Cho, J. K. SaKong, E. J. Kim, and S. W. Lim. "P.4.a.003 Negative and biased facial emotion recognition of social anxiety disorder patients." European Neuropsychopharmacology 23 (October 2013): S508—S509. http://dx.doi.org/10.1016/s0924-977x(13)70807-1.
Full text
33
Surya, Yenni Fitra. "PENERAPAN MODEL PEMBELAJARAN KOOPERATIF TIPE TEAM GAMESTOURNAMENT (TGT) UNTUK MENINGKATKAN HASIL BELAJARMATEMATIKA SISWA KELAS V SEKOLAH DASAR NEGERI 003 BANGKINANG KOTA." Jurnal Cendekia : Jurnal Pendidikan Matematika 2, no. 1 (May 1, 2018): 154–63. http://dx.doi.org/10.31004/cendekia.v2i1.41.
Full textAbstract:
Penelitian ini dilatarbelakangi oleh rendahnya hasil belajar Matematika diperoleh siswa kelas V secara klasikal masih berada di bawah ketuntasan yang ditetapkan yaitu 85%. Berdasarkan observasi awal yang dilakukan di Sekolah Dasar Negeri 003 Bangkinang dijumpai gejala-gejala seperti: 1) Hasil tes pada siswa kelas V Sekolah Dasar Negeri 003 Bangkinang diperoleh fakta tentang hasil belajar Matematika dari 33 siswa ternyata yang mencapai KKM yang ditetapkan sekolah yaitu 70 sebanyak 13 orang siswa (39.39%) dan yang tidak mencapai KKM sebanyak 20 siswa (59,4%) dengan nilai rata-rata 67,5. 2) Siswa cenderung bosan dalam mengikuti pelajaran Matematika, 3) Kurangnya keingintahuan siswa terhadap pelajaran yang disampaikan oleh guru di kelas, dan 4) Selama ini guru cenderung menjelaskan materi, memberikan contoh soal dan memberi latihan dengan cara yang monoton. Penelitian ini bertujuan untuk mengetahui peningkatan hasil belajar Matematika pada materi pecahan siswa kelas V Sekolah Dasar Negeri 003 Bangkinang melalui penerapan model pembelajaran kooperatif tipe Team Games Tournament (TGT).
Penelitian ini merupakan penelitian tindakan kelas.penelitian tindakan kelas merupakan suatu pencermatan terhadap kegiatan belajar berupa sebuah tindakan yang sengaja dimunculkan dan terjadi dalam sebuah kelas secara bersama. Tindakan tersebut diberikan oleh guru atau dengan arahan dari guru yang dilakukan oleh siswa.Penelian ini telah dilaksanakan di kelas V Sekolah Dasar Negeri 003.
Berdasarkan hasil penelitian, maka dapat diketahui bahwa Ketuntasan belajar siswa meningkat pada siklus I dari 33 orang siswa, yang mencapai ketuntasan berjumlah 20 orang siswa (60.6%) dan siswa yang tidak tuntas 13 orang (39.4%). Sedangkan pada siklus II siswa yang dikatakan tuntas 29 orang (87.9%) dan siswa yang tidak tuntas 4 orang (12.1%). Sedangkan nilai rata-rata peningkatan hasil belajar siswa dari data awal ke siklus I sebesar 5.5 dan dari siklus I ke siklus II juga mengalami peningkatan sebesar 10,30.
34
Chowdhury, Fazle Rabbi, Quazi Mamtaz Uddin Ahmed, and Shrebash Paul. "The Quest for an Effective Dengue Vaccine: Hope or Hype." Journal of Medicine 25, no. 1 (January 4, 2024): 58–67. http://dx.doi.org/10.3329/jom.v25i1.70361.
Full textAbstract:
Several trials are ongoing to develop a safe and effective vaccine to prevent dengue virus (DENV) infections, especially avoiding the risk of antibody-dependent enhancement. Only three of them (Dengvaxia/CYTTDV, Takeda TAK-003, and NIH TV-003/TV-005) have shown promising results. The issue of ‘hyperendemicity’ and ‘quasi-species the major challenge behind developing a successful vaccine. The overall efficacy of first successful vaccine ‘Dengvaxia’ showed 30.2%–60.8% efficacy with limited protection against DEN 1 and DEN 2. In Bangladesh, since 2019, outbreaks have mostly been caused by DEN 2 and DEN 3, and the trend is predicted to continue for the coming years. TAK-003 gives almost no protection against DEN 3, which is the most notorious serotype encircling Bangladesh. The overall efficacy of this vaccine is 62%, with limited protection against DEN 4. NIH TV-003/TV-005 currently shows more promise with an overall efficacy of 80%. However, we have to wait until June 2024 for the final results. All of these vaccines are safe and effective for travelers. However, for mass vaccination, a country should make a decision based on their prevalent serotypes and the potential serotypes that might cause the next epidemic. To gather these data, a robust serotype- and genotype-based surveillance system and warning system should be in place. J MEDICINE 2024; 25: 58-67
35
Pallanti, S., S. Antonini, S. Bernardi, and E. Hollander. "P.4.c.003 Ondansetron augmentation in resistant OCD: relapse in symptoms following discontinuation of ondansetron." European Neuropsychopharmacology 20 (August 2010): S542—S543. http://dx.doi.org/10.1016/s0924-977x(10)70816-6.
Full text
36
Kennis, M., S. Van Rooij, M. Van den Heuvel, R. Kahn, and E. Geuze. "P.4.d.003 Treatment-related functional orbitofrontal network alterations in veterans with posttraumatic stress disorder." European Neuropsychopharmacology 25 (September 2015): S568. http://dx.doi.org/10.1016/s0924-977x(15)30795-1.
Full text
37
Alonso, P., C. Segalas, E. Real, C. López-Solà, G. Plans, M. A. Aparicio, and J. M. Menchon. "P.4.b.003 Symptom dimensions and response to deep brain stimulation in obsessive–compulsive disorder." European Neuropsychopharmacology 23 (October 2013): S512—S513. http://dx.doi.org/10.1016/s0924-977x(13)70813-7.
Full text
38
Tomkinson, A., L. Stevens, M. Morton, A. Bowden, T. Wong, D. Boisvert, K. Delaria, and E. Burmeister Getz. "AER 003, a PEGylated IL-4/IL-13 Antagonist, Significantly Reduces Allergen-Induced Airway Hyperresponsiveness (AHR)." Journal of Allergy and Clinical Immunology 125, no. 2 (February 2010): AB54. http://dx.doi.org/10.1016/j.jaci.2009.12.246.
Full text
39
Tricou, Vianney, Shibadas Biswal, Mengya Liu, Sanjay S. Patel, Olaf Zent, Martina Rauscher, Gonzalo Perez, Walid Kandeil, and Nicolas Folschweiller. "97. Tetravalent Dengue Vaccine (TAK-003) Development Program: A Bird’s Eye View." Open Forum Infectious Diseases 8, Supplement_1 (November 1, 2021): S61. http://dx.doi.org/10.1093/ofid/ofab466.097.
Full textAbstract:
Abstract Background Dengue fever is a mosquito-borne viral disease endemic in 128 countries. An unmet clinical need remains for an effective vaccine that can be used more broadly than the vaccine presently available. A clinical development program has evaluated the long-term safety, immunogenicity, and vaccine efficacy (VE) of TAK-003, a live attenuated tetravalent dengue vaccine with a DENV-2 backbone engineered to elicit immune responses to all 4 dengue serotypes. Methods 18 clinical trials in 13 countries have involved 28,175 seropositive/seronegative participants aged from 1.5-60 years from endemic/non-endemic regions. In the ongoing pivotal phase III study, 4–16-year-old healthy children (N=20,099) were randomized 2:1 to receive two doses of TAK-003 or placebo, 3 months apart for an evaluation of VE and safety over a multi-year period stratified pre-vaccination dengue serostatus. Active surveillance throughout the trial detected symptomatic dengue. The trial will continue up to 4–4.5 years post 2nd dose, and for another 25 months after a booster dose. Data up to 3 years after the second vaccination are currently available. Results Safety and immunogenicity data from Phase I/II studies established the final formulation and dosing schedule. Overall VE in the pivotal phase III study was 80.2% [95% CI: 73.3–85.3] against virologically confirmed dengue (VCD) at 12 months post 2nd dose. At 18 months, VE was 66.2% (95% CI: 49.1–77.5) in dengue-naive and 76.1% (95% CI: 68.5–81.9) in dengue pre-exposed participants, with VE of 90.4% (95% CI: 82.6–94.7) and 85.9% (95% CI: 31.9–97.1) for prevention of hospitalized VCD and dengue hemorrhagic fever, respectively. Cumulative VE against VCD from first dose to 3 years post 2nd dose was 62.0% (95% CI: 56.6–66.7) and 83.6% (95% CI: 76.8–88.4) in prevention of hospitalized VCD. Some decline in VE was observed over time mainly driven by outpatient dengue. Two doses of TAK-003 3 months apart were well-tolerated with no important safety risks identified up to 3 years after completion of the vaccination schedule. Conclusion TAK-003 is immunogenic against all 4 dengue serotypes and continues to be efficacious, well-tolerated, and with no evidence of disease enhancement in seronegative population up to 3 years post-vaccination. Disclosures Vianney Tricou, D Phil, Takeda Pharmaceuticals International (Employee) Shibadas Biswal, MD, Takeda Vaccines, Inc (Employee) Sanjay S. Patel, PhD, Takeda Pharmaceuticals International AG (Employee) Olaf Zent, MD, Takeda Pharmaceuticals International AG (Employee) Martina Rauscher, PhD, Takeda Pharmaceuticals International AG (Employee) Gonzalo Perez, MD, Takeda group companies (Employee) Walid Kandeil, MD, Takeda Pharmaceuticals International AG (Employee) Nicolas Folschweiller, PhD, Takeda (Employee)
40
Siegel, David S., Paul G. Richardson, Meletios A. Dimopoulos, Christine I. Chen, Kevin Song, Ravi Vij, Nizar J. Bahlis, et al. "Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003)." Blood 122, no. 21 (November 15, 2013): 3185. http://dx.doi.org/10.1182/blood.v122.21.3185.3185.
Full textAbstract:
Abstract Introduction Few treatments options are available for patients (pts) with relapsed/refractory multiple myeloma (RRMM) who have previously been treated with lenalidomide (LEN) and bortezomib (BORT), and their prognosis is poor. Pomalidomide (POM) is a distinct IMiD® immunomodulatory agent with a mechanism of action consisting of direct anti-myeloma, stromal-support inhibitory, and immunomodulatory effects. In randomized phase 2 and 3 trials (MM-002 and MM-003), POM plus low-dose dexamethasone (POM+LoDEX) demonstrated marked efficacy in RRMM pts who had received multiple prior therapies, including LEN and BORT. This side-by-side analysis presents the most recent survival and safety data from these trials. Methods The MM-002 and MM-003 trials enrolled pts with ≥ 2 prior therapies, including LEN and BORT. In MM-002, pts received POM (4 mg/day on days 1–21 of each 28-day cycle) alone or in combination with LoDEX (40 mg/week). In MM-003, pts were randomized 2:1 to receive POM+LoDEX or high-dose DEX alone (HiDEX) (40 mg/days 1–4, 9–12, 17–20 in a 28-day cycle); HiDEX was chosen as the comparator to isolate the effects of POM, as at the time of trial design it was the standard salvage therapy for heavily pretreated pts. Thromboprophylaxis was required for all pts treated with POM and pts at high risk of developing venous thromboembolism. Data cutoff was February 1, 2013 for MM-002 and March 1, 2013 for MM-003. The primary endpoint in both trials was progression-free survival (PFS). Secondary endpoints included overall survival (OS), response rates, duration of response, and safety. Results In each study, pts had received a median of 5 prior therapies (range 1-17), and all pts had received prior LEN and BORT. In MM-002, 113 pts were treated with POM+LoDEX and 108 were treated with POM alone (60% of POM alone pts subsequently received DEX). A total of 79% of pts were LEN refractory; 62% were refractory to both LEN and BORT; and 35% had received LEN as their last prior therapy. With a median follow-up of 14.2 months (mos), median PFS was 4.2 mos, OS was 16.5 mos, and overall response rate (ORR, defined as at least a partial response) was 33% with POM+LoDEX (Table 1). In MM-003, 302 pts were treated with POM+LoDEX and 153 pts were treated with HiDEX (50% of HiDEX pts subsequently received POM). A total of 94% of pts were LEN refractory; 74% were both LEN and BORT refractory; and 29% had received LEN as their last prior therapy. Survival outcomes were similar in MM-003; with a median follow-up of 10 mos, median PFS was 4.0 mos, OS was 12.7 mos, and ORR was 31% with POM+LoDEX. In both trials, LEN as last prior therapy did not impact response, PFS, or OS vs the overall population. Commonly observed adverse events (AEs) are presented in Table 2 for pts treated with POM+LoDEX. Grade 3 and 4 neutropenia was 28% and 13% in MM-002, and 26% and 22% in MM-003 for the POM+LoDEX arms, respectively. AEs were generally manageable for POM+LoDEX in MM-002 and MM-003 with dose interruptions (67% for both) and reductions (29% and 26%, respectively), and standard supportive care, including growth factor support (46% and 43%), red blood cell transfusions (45% and 49%), platelet transfusions (14% and 20%), and anti-infective agents (89% in both trials). Rates of POM discontinuation due to treatment-related AEs were low (2–4% with POM+LoDEX). In MM-002 and MM-003, 49% and 51% of pts in the POM+LoDEX arms experienced neutropenia of any grade. With appropriate AE management, 9% and 23% had dose interruptions, 4% and 8% had dose reductions, and 1 pt in both MM-002 and MM-003 discontinued due to neutropenia. Febrile neutropenia developed in 3% and 10% of pts; 1% and 4% had dose interruptions, 0% and 2% had dose reductions, and no pts discontinued due to febrile neutropenia in the MM-002 and MM-003 studies, respectively. The majority of infections occurred in the absence of neutropenia of any grade (54% in MM-002 and 66% in MM-003). The rate of POM discontinuation due to infection was low (1% in MM-002 and 2% in MM-003). Conclusion In both the MM-002 and MM-003 trials, POM+LoDEX consistently extended PFS in advanced RRMM pts. PFS, OS, and ORR were not negatively impacted in patients who were refractory to LEN or BORT, even as last prior therapy. Both trials demonstrated that with dose modifications and supportive care POM was well tolerated, leading to few discontinuations. POM+LoDEX should be considered a standard of care for pts with advanced RRMM who have exhausted LEN and BORT. Disclosures: Siegel: Celgene Corporation: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Onyx: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Millennium: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau. Richardson:Millennium: Membership on an entity’s Board of Directors or advisory committees; Johnson & Johnson: Membership on an entity’s Board of Directors or advisory committees; Celgene Corporation: Membership on an entity’s Board of Directors or advisory committees. Dimopoulos:Celgene Corporation: Honoraria, Membership on an entity’s Board of Directors or advisory committees. Chen:Celgene Corporation: Consultancy, Honoraria, Research Funding. Song:Celgene Corporation: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding, Speakers Bureau. Vij:Onyx: Consultancy, Research Funding; Millenium: Speakers Bureau; Celgene Corporation: Consultancy, Research Funding, Speakers Bureau. Bahlis:Celgene Corporation: Consultancy, Honoraria, Research Funding. Baz:Millenium: Research Funding; Bristol Myers Squibb: Research Funding; Novartis: Research Funding; Karyopharm: Research Funding; Sanofi: Research Funding; Celgene Corporation: Research Funding. Hofmeister:Celgene Corporation: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau. Weisel:Celgene Corporation: Consultancy, Honoraria, Research Funding. Jagannath:Millennium: Honoraria; Celgene Corporation: Honoraria. Lonial:Millennium: Consultancy; Novartis: Consultancy; Bristol Myers Squibb: Consultancy; Sanofi: Consultancy; Onyx: Consultancy; Celgene Corporation: Consultancy. Delforge:Celgene Corporation: Honoraria. Talpaz:Ariad, Sanofi, Novartis: Membership on an entity’s Board of Directors or advisory committees; Ariad, Novartis, BMS, Pfizer: Speakers Bureau; Ariad, BMS, Sanofi, INCYTE: Research Funding. Moreau:Celgene Corporation: Honoraria, Speakers Bureau. San Miguel:Jansen, Celgene Corporation, Onyx, Novartis, Millenium: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees. Karlin:Janssen: Honoraria; Celgene Corporation: Consultancy, Expert board committee Other, Honoraria. Goldschmidt:Celgene Corporation, Janssen, Novartis: Consultancy, Honoraria, Research Funding. Oriol:Celgene Corporation: Consultancy. Alegre:Janssen: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Celgene Corporation: Membership on an entity’s Board of Directors or advisory committees, Research Funding. Cavo:Millennium: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Janssen: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Onyx: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Celgene Corporation: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees. Martinez-Lopez:Celgene Corporation: Honoraria, Research Funding. Lacy:Celgene Corporation: Research Funding. Chen:Celgene Corporation: Employment, Equity Ownership. Casey:Celgene Corporation: Employment, Equity Ownership. Sternas:Celgene Corporation: Employment, Equity Ownership. Zaki:Celgene Corporation: Employment, Equity Ownership. Jacques:Celgene Corporation: Employment, Equity Ownership. Anderson:Onyx: Consultancy, Equity Ownership; Gilead: Consultancy, Equity Ownership; sanofi aventis: Consultancy, Equity Ownership; Oncopep: Consultancy, Equity Ownership; Acetylon: Consultancy, Equity Ownership; Celgene Corporation: Consultancy, Equity Ownership.
41
Gusliani, Ema, Kasman Ediputra, and Fadhilaturrahmi Fadhilaturrahmi. "Efforts to Increase Student’s Critical Thinking Ability Using Problem Based Learning Model for Elementary School Students." Edumaspul: Jurnal Pendidikan 5, no. 2 (October 1, 2021): 160–65. http://dx.doi.org/10.33487/edumaspul.v5i2.2015.
Full textAbstract:
Penelitian ini dilatar belakangi oleh rendahnya kemampuan berpiki kritis siswa di kelas IV SDN 003 Batu Bersurat. Salah satu solusi untuk mengatasi masalah ini adalah dengan menggunakan model Problem Based Learning (PBL). Tujuan penelitian ini untuk memaparkan peningkatan kemampuan berpikir kritis siswa dengan menggunakan model Problem Based Learning (PBL) pada siswa kelas IV SDN 003 Batu Bersurat. Metode penelitian ini adalah Penelitian Tindakan Kelas (PTK) yang dilaksanakan dalam dua siklus. Setiap siklus terdapat dua pertemuan dan empat tahap, yaitu perencanaan, pelaksanaan, observasi, dan refleksi. Waktu penelitian dilaksanakan pada bulan Juni selama dua minggu 2021. Subjek penelitian ini siswa kelas IV yang berjumlah 14 siswa. Dengan jumlah laki-laki 4 siswa, dan siswa perempuan 10 siswa. Teknik pengumpulan data berupa tes, observasi, dan dokumentasi. Hasil penelitian ini dapat disimpulkan bahwa kemampuan berpikir kritis siswa mengalami peningkatan pada setiap siklus, dimana hasil persentase pada siklus I pertemuan I mencapai (43%), pertemuan II meningkat menjadi (57%) sedangkan pada siklus II pertemuan I (71%), dan pertemuan II meningkat mencapai (86%). Dengan demikian dapat disimpulkan bahwa dengan menerapkan model Problem Based Learning (PBL) dapat meningkatkan kemampuan berpikir kritis siswa materi bentuk keberagaman yang terikat persatuan dan kesatuan pada kelas IV SDN 003 Batu Bersurat.
42
Reincke, Martin, Michael Peter, Wolfgang G. Sippell, and Bruno Allolio. "Impairment of 11β-hydroxylase but not 21-hydroxylase in adrenal 'incidentalomas'." European Journal of Endocrinology 136, no. 2 (February 1997): 196–200. http://dx.doi.org/10.1530/eje.0.1360196.
Full textAbstract:
Abstract Recent reports have shown an exaggerated response of 17-hydroxyprogesterone in up to 70% of patients with incidentally detected adrenal adenomas ('incidentalomas'). This has been explained by pre-existing 21-hydroxylase deficiency which may be a pathogenetic factor in the development of adrenal tumours. However, other defects in steroidogenesis, such as mild 11β-hydroxylase deficiency, could also result in increased 17-hydroxyprogesterone secretion. We therefore studied the glucocorticoid and mineralocorticoid pathways in patients with adrenal 'incidentalomas' by measuring multiple adrenal steroids before and after 1–24 ACTH stimulation. Twenty patients with adrenal 'incidentalomas' (14 females, 6 males) and 27 healthy controls (14 females, 13 males) were studied. All subjects underwent a 1–24 ACTH stimulation test (250 μg i.v.) with determination of progesterone, 11-deoxycorticosterone, corticosterone, 17-hydroxyprogesterone, 11-deoxycortisol and cortisol at O and 60 min. All steroids were measured by RIA after extraction and HPLC. Patients with 'incidentalomas' had higher stimulated concentrations of 17-hydroxyprogesterone (21·6 ± 8·4 vs 4·2 ± 0·3 nmol/l; P ≤ 0·001), 11-deoxycortisol (8·1 ± 1·2 vs 3·6 ± 0·3 nmol/l; P ≤ 0·001), progesterone (8·28 ± 2·82 vs 1·08 ± 0·15 nmol/l; P ≤ 0·001), and 11-deoxycorticosterone (2·1 ± 0·39 vs 0·78 ± 0·12 nmol/l; P = 0·002) compared with controls. In contrast, cortisol and corticosterone concentrations were not different. There was evidence for impairment of 11β-hydroxylase activity by an increased 11-deoxycortisol/cortisol ratio (0·012 ± 0·003 vs 0·005 ± 0·001 in controls; P = 0·002) and 11-deoxycorticosterone/corticosterone ratio (0·04 ± 0·003 vs 0·015 ± 0·003; P = 0·003). The conclusions reached were that patients with adrenal 'incidentalomas' have increased responses of precursors of the mineralocorticoid and glucocorticoid pathway including 17-hydroxyprogesterone after stimulation with ACTH. This seems to be caused by impairment of 11β-hydroxylase activity rather than by impaired 21-hydroxylase activity in these tumours. European Journal of Endocrinology 136 196–200
43
Fenaux, Pierre, Agnes Guerci-Bresler, Petra Muus, Mikkael A. Sekeres, Aristoteles Giagounidis, H. Joachim Deeg, Peter Greenberg, Barry Skikne, Xujie Yu, and Alan F. List. "Efficacy and tolerability of lenalidomide (LEN) in patients (pts) 75 and older versus those younger than 75 with RBC transfusion-dependent low/int-1-risk MDS and del 5q." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): 6522. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.6522.
Full textAbstract:
6522 Background: LEN is the approved treatment for pts with RBC transfusion-dependent Low/Int-1-risk MDS and del 5q. In 2 multicenter trials (MDS-003/-004) LEN lead to RBC transfusion independence (TI) for ≥ 26 wks in 35–58% of pts and cytogenetic response (CyR) in 25–73%. Most common grade (G) 3–4 adverse events (AE) were neutropenia and thrombocytopenia, a safety concern in elderly pts. We evaluated efficacy and tolerability of LEN in pts ≥ 75 y vs < 75 y in MDS-003/-004 trials. Methods: Pts received LEN 5 mg × 28 d, 10 mg × 21 d, or 10 mg × 28 d (all 28 d cycles). Dose reductions were required for G4 neutropenia (both trials) and platelet counts < 30 x 109/L (MDS-003) or < 25 x 109/L (MDS-004). Results: 32% of the 286 pts were ≥ 75 y. Baseline (BL) characteristics, LEN treatment, and optional G-CSF use are shown in Table. In pts ≥ 75 y vs < 75 y: RBC-TI ≥ 26 wks was 39 vs 47% (P = NS); CyR was 64 vs 54% (P = NS); 2-y AML progression rates were 10 vs 19% (P = NS); 2-y overall survival rates were 62 vs 73% (P = .001); G3–4 AE: neutropenia (63 vs 76%; P = .024), thrombocytopenia (56 vs 49%; P = NS), infection (36 vs 20%; P = .003); median time to recovery to ANC > 1 x 109/L was 0.7 vs 0.7 mo (P = NS) and to platelet counts > 100 x 109/L was 3.3 vs 1.7 mo (P = NS). 59% pts ≥ 75 y and 49% pts < 75 y discontinued LEN due to AE (33 vs 26%; P = NS), lack of effect (32 vs 49%; P = NS), or death (15 vs 6%; P = NS). Dose reduction and discontinuation rates are shown in Table. Conclusions: Pts ≥ 75 y and < 75 y had comparable response and AML progression rates. In pts ≥ 75 y, LEN appears to be well tolerated but the higher infection rate justifies close follow-up. [Table: see text]
44
Witzig, Thomas E., Julie Vose, Pier Luigi Zinzani, Thomas Matthew Habermann, Joseph M. Tuscano, Rajni Sinha, Michael E. Williams, et al. "Combined analysis of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma." Journal of Clinical Oncology 31, no. 15_suppl (May 20, 2013): 8533. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.8533.
Full textAbstract:
8533 Background: Mantle cell lymphoma (MCL) is an aggressive form of non-Hodgkin lymphoma (NHL) with poor prognosis. The immunomodulatory agent lenalidomide shows consistent activity with tolerable safety in multiple phase II studies of relapsed/refractory aggressive NHL (NHL-002 and NHL-003) and MCL post-bortezomib (MCL-001). This pooled analysis further examined the efficacy and safety of single-agent lenalidomide in patients with relapsed/refractory MCL. Methods: Single-agent lenalidomide was given 25 mg/d PO on days 1-21 of 28-day cycles as tolerated for 52 weeks (NHL-002) or until disease progression (NHL-003 and MCL-001). All MCL patients received ≥1 prior treatment, including bortezomib in MCL-001. Efficacy data were examined by independent central review for MCL-001 and NHL-003 and by investigators for NHL-002. Results: 206 patients with relapsed/refractory MCL were studied. The median age was 67 y (range 33-84; 63% ≥65 y), 91% stage III/IV disease and 51% had received ≥4 prior regimens (76% prior bortezomib). Overall response rate (ORR) with lenalidomide was 32% (10% CR/CRu), with a median time to response of 2.1 months and median duration of response (DOR) of 16.6 months (not yet reached in patients with CR/CRu; Table). Kaplan-Meier estimates for median PFS and OS were 5.4 and 23.9 months, respectively. Mean daily dose of lenalidomide was 21 mg. Grade 3/4 AEs included neutropenia (44%), thrombocytopenia (29%), anemia (11%), and fatigue (7%). Other any-grade AEs included tumor flare reaction (7%), venous thromboembolic events (7%), and invasive second primary malignancies (3%). Conclusions: Lenalidomide produced rapid and durable responses in patients with relapsed/refractory MCL, and exhibited a predictable safety profile among 3 phase II studies of lenalidomide in heavily pretreated patients, including prior treatment with bortezomib. Clinical trial information: MCL-001: NCT00737529; NHL-002: NCT00179660; NHL-003: NCT00413036. [Table: see text]
45
Harahap, Amir Hakim. "PENINGKATAN KEMAMPUAN MENULIS PANTUN DENGAN MENGGUNAKAN TEKNIK JEJAKA SISWA KELAS IV SDN 003 SUNGAI SALAK KECAMATAN TEMPULING." Selodang Mayang: Jurnal Ilmiah Badan Perencanaan Pembangunan Daerah Kabupaten Indragiri Hilir 7, no. 1 (April 29, 2021): 48–52. http://dx.doi.org/10.47521/selodangmayang.v7i1.199.
Full textAbstract:
Abstract
The problem of Classroom Action Research (PTK) is the low learning outcomes of Indonesian in poetry writing material for Grade IV students of SDN 003 Sungai Salak, Tempuling Regency. achieved by students, 70. Pantun is written by students of plagiarism or rhymes created by others. Nobody writes poetry with their own work. This learning problem was overcome by using the Acronym Technique of Exploration Words Exploration: problem formulation Is the application of the Trace Technique able to improve students' writing skills in Class IV SDN 003 Sungai Salak, Tempuling Regency? This study aims to improve Indonesian language learning outcomes in rhyming writing material. This research is expected to be useful for students, teachers, the community, and the Indragiri Hilir Regency Education Office. Based on the results of research Learning conducted using youth techniques has significantly improved learning outcomes. In the pre-cycle no students had finished learning (0%); in the first cycle with undergraduate techniques 4 students (18.18%) completed learning with an average grade of 47.30 (less category); and in cycle II as many as 20 students (90.90%) had completed their studies with an average grade of 82.27, (Good category). Based on research results increasing learning with young techniques succeeded in increasing the problem of low poetry writing skills of Class IV SDN 003 Sungai Salak students, Tempuling Regency. Students have been able to understand and create poetry with their own work.
Abstrak
Permasalahan Penelitian Tindakan Kelas (PTK) ini adalah dari rendahnya hasil belajar Bahasa Indonesia pada materi menulis pantun siswa Kelas IV SDN 003 Sungai Salak Kecamatan Tempuling, Ini terlihat dari hasil belajar, tidak ada siswa (0%) yang mencapai target minimal hasil belajar yang harus dicapai siswa, 70. Pantun yang ditulis siswa plagiat atau pantun ciptaan orang lain. Tidak ada seorang pun yang menulis pantun dengan karya sendiri. Masalah belajar ini diatasi dengan menggunakan Teknik Jejaka akronim dari Jelajah Sajak kata: rumusan masalah Apakah penerapan Teknik Jejaka dapat meningkatkan kemampuan menulis pantun siswa Kelas IV SDN 003 Sungai Salak Kecamatan Tempuling? Penelitian bertujuan untuk untuk meningkatkan hasil belajar Bahasa Indonesia materi menulis pantun. Penelitian diharapkan bermanfaat bagi siswa, guru, masyarakat, dan Dinas Pendidikan Kabupaten Indragiri Hilir. Berdasarkan hasil penelitian Pembelajaran yang dilaksanakan dengan menggunakan teknik jejaka berhasil meningkatkan hasil belajar secara signifikan. Pada prasiklus tidak ada siswa yang tuntas belajar (0%) ; pada siklus I dengan teknik jejaka 4 siswa (18,18%) tuntas belajar dengan nilai rata-rata 47,30 (kategori Kurang); dan pada siklus II sebanyak 20 siswa (90,90%) telah tuntas belajar dengan nilai rata-rata kelas 82,27, (kategori Baik). Berdasarkan hasil penelitian perbaikan pembelajaran dengan teknik jejaka berhasil memperbaiki masalah rendahnya kemampuan menulis pantun siswa Kelas IV SDN 003 Sungai Salak Kecamatan Tempuling. Siswa-siswa telah dapat memahami dan mencipta pantun dengan karya sendiri.
46
Khan, Parvez. "Comparative Study of Efficacy and Safety of Coded Unani Formulations–UNIM-001+UNIM-003 with Methoxsalen in Cases of Bars (Vitiligo)." JOURNAL OF ADVANCED RESEARCH IN AYURVEDA, YOGA, UNANI, SIDHHA & HOMEOPATHY 07, no. 3&4 (December 31, 2020): 16–26. http://dx.doi.org/10.24321/2394.6547.202009.
Full textAbstract:
Background: Vitiligo is a common acquired disorder of skin depigmentation in varying patterns, varying from small maculae’s with scalloping borders to near total depigmentation of body. The prevalence of vitiligo in India has been invariably reported between 0.25% and 4% of dermatology outpatients across studies from India and up to 8.8% in Gujarat and Rajasthan. The study was conducted to compare the coded Unani formulation UNIM-001 (tablet) and UNIM-003 (ointment) with Melanocyl tablet (10mg each) (Methoxsalen) as standard control. Methodology: Sixty Five patients of trial group (UNIM-001+ UNIM-003) and sixty seven patients of control group (Comparator group) of 12-50 years of either sex were selected from patients attending the Out Patient Department (OPD), at RRIUM, Aligarh during 2015-18. The patients were treated for eight months with instructions and are followed every month for efficacy and safety of the drug(s). The CRF was maintained, and post treatmet followup was done at 3 months for the repigmentaion retained by the patient. Result: The UNIM-001 (tablets) and UNIM -003 (ointment) and standard control drug Melanocyl tablets (methoxsalen) showed same results and did not show any side effects. Conclusion: The trial drug and the standard control drugs both possess same anti- vitiligo efficacy and are also safe for the patients.
47
Shin, Sooncheon, Beniamin Filimon, Yuefeng Yang, Zebin Hu, Prem Seth, Vijayakrishna K. Gadi, and Weidong Xu. "Abstract PD2-03: Targeting TGF-β and over-expressing GM-CSF in the Tumor Microenvironment (TME) with AMUN-003 Inhibits Tumor Growth and Metastases and Augments Immune Checkpoint Inhibitor (ICI) Response in Triple Negative Breast Cancer (TNBC)." Cancer Research 83, no. 5_Supplement (March 1, 2023): PD2–03—PD2–03. http://dx.doi.org/10.1158/1538-7445.sabcs22-pd2-03.
Full textAbstract:
Abstract Introduction: Despite several therapeutic advancements, metastatic TNBC remains incurable for nearly all patients and is a frequent cause of cancer-related deaths worldwide. We tested the hypothesis that inhibiting suppressive signals sustained by TGF-β and concurrently stimulating recruitment of inflammatory cells with GM-CSF within the TME would result in improved anti-tumor responses. We report here pre-clinical single agent and ICI combination data for a newly developed oncolytic adenovirus rAd.sT.GM (AMUN-003) that expresses both sTGFβRIIFc (a TGF-β protein decoy), and GM-CSF tested in an immunocompetent mouse model. Methods: In addition to manufacturing Amun-003 which is a replication competent adenovirus encoding both sTGFβRIIFc and GM-CSF transgenes, we generated multiple replication competent control viruses coding for sTGFβRIIFc alone, GM-CSF alone or no transgene. We implanted 4T1 cells in the flanks of BALB/c mice, a syngeneic tumor model that is immune competent. On day 7 and day 10 post tumor cell inoculation, we performed saline or single agent virus injections into the tumor. We monitored the health of the animals, performed periodic tumor caliper measurements and collected sera for analysis of cytokines and markers of tissue injury. Animals were sacrificed on Day 25 and tissues collected. Similarly, with the same animal model and using reduced dose Amun-003, we tested combinations with systemic anti-CTLA-4, anti-PD-1 monoclonal antibodies, or both. Animals were sacrificed on Day 25 with specimens collected as above but also to report the metastatic burden in distant tissues. Results: In single agent experiments, all adenovirus constructs were similarly tolerated by the animals with no notable differences in animal weights. General safety as assessed by serum LDH and IL-6 demonstrated no difference between animal groups treated with the different virus constructs. All adenovirus resulted in delay of cancer growth and on day 25, excised tumors from sacrificed animals weighed less than tumors from animals treated with buffer. However, a single dose of Amun-003 was the most effective at delaying tumor progression than any other tested constructs (Day 21 and Day 25: P < 0.0001 vs the buffer group by two-way ANOVA analysis). Next, we conducted experiments evaluating a single dose of Amun-003 alone or in combination with anti-CTLA4, anti-PD1 or both ICI. Combinations of Amun-003 with ICI delayed progression better than ICI treatments alone or Amun-003 alone. Moreover, the combination with both ICI and Amun-003 was most effective at delay of tumor progression (Day 22 and Day 25: P < 0.0001 vs the buffer group; D25: P=0.0119 vs dual ICI therapy). Lung surface metastatic nodule counts and lung tissue luciferase assay for 4T1-luc2 cells both showed treatment consisted of Amun003 and both ICI was most potent in inhibiting lung metastasis (Lung nodules: P < 0.0001 vs the buffer group; Relative luminescence: P=0.0036 vs the buffer group, both by one-way ANOVA analysis). Finally, the metastatic burden in the lung was least in animals treated with Amun-003 and both ICI (42% metastases free) (P = 0.0373 vs the buffer group by fisher’s exact test). Conclusions: In syngeneic immune competent animals harboring an aggressive TNBC tumor, single agent Amun-003 appeared safe and was more effective at controlling tumor progression following an intratumoral injection when compared to other tested adenovirus constructs. In the same model, combinations of ICI with Amun-003 resulted in delayed tumor growth and control of metastatic spread. These results with Amun-003 support advancement to human clinical testing. Citation Format: Sooncheon Shin, Beniamin Filimon, Yuefeng Yang, Zebin Hu, Prem Seth, Vijayakrishna K. Gadi, Weidong Xu. Targeting TGF-β and over-expressing GM-CSF in the Tumor Microenvironment (TME) with AMUN-003 Inhibits Tumor Growth and Metastases and Augments Immune Checkpoint Inhibitor (ICI) Response in Triple Negative Breast Cancer (TNBC) [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr PD2-03.
48
Mejri, Sami B. "Examining the Correlation between American Students’ Cultural Intelligence, Political Affiliations, and Their Social Distances from Their International Peers." Journal of International Students 9, no. 3 (August 15, 2019): 873–95. http://dx.doi.org/10.32674/jis.v0i0.81.
Full textAbstract:
Guided by the theories of cultural intelligence and social distance, the purpose of this quantitative non-experimental study was to determine whether first-year American-born college students’ political party affiliations and cultural intelligence (CQ) relate to their self-reported social distances (SDs) from international students. One hundred and twenty-one first-year college students at a 4-year Midwestern university participated in this study. Regression analysis showed that political party affiliation (β = .194, t = 3.074, p = .003), metacognitive CQ (β = −.239, t = −.2.885, p = .005), motivational CQ (β = −.363, t = −4.225, p = .001), and behavioral CQ (β = −.215, t = −3.078, p = .003) of American-born college students were statistically significant predictors of their social distances from international peers. However, cognitive CQ (β = .009, t = .112, p = .911) was not a statistically significant predictor of social distance between these two groups of students.
49
Amaral, V. C. S., and R. L. Nunes-de-Souza. "P.4.b.003 Distinct role of the ventral hippocampus in two different animal models of anxiety." European Neuropsychopharmacology 20 (August 2010): S531. http://dx.doi.org/10.1016/s0924-977x(10)70795-1.
Full text
50
Diniz, J. B., C. A. B. Pereira, E. C. Miguel, and R. G. Shavitt. "P.4.e.003 Clomipramine and quetiapine augmentation for obsessive compulsive disorder compared to sustained fluoxetine treatment." European Neuropsychopharmacology 20 (August 2010): S547—S548. http://dx.doi.org/10.1016/s0924-977x(10)70824-5.
Full text